Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects
Status:
Completed
Trial end date:
2021-09-27
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label study to assess the safety and intrapulmonary
pharmacokinetics of cefepime and taniborbactam in healthy adult male and female subjects.
Thirty subjects will receive a total of 6 doses of cefepime-taniborbactam (2 g cefepime/0.5g
taniborbactam) administered intravenously every 8 hours. Following the sixth dose of
cefepime-taniborbactam, subjects will be assigned to one of six bronchoscopy sampling times.